Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations
SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ: FLDM) and Indica Labs, Inc. , today announced a co-marketing relationship for scalable and simple-to-use tissue image analysis for Imaging Mass Cytometry ™ (IMC ™ ).
View HTML
Toggle Summary Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases
Gaining insights into inflammatory bowel disease through mass cytometry and Imaging Mass Cytometry analysis of the human mucosal immune system Research aimed at more precise treatments for IMIDs using existing therapies and identification of new targets for drug development SOUTH SAN FRANCISCO,
View HTML
Toggle Summary Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1
First commercially available, automated single-cell analysis application to enable co-detection of cellular protein and RNA expression using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), a leader in mass cytometry and
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 , after the close of
View HTML
Toggle Summary Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
View HTML
Toggle Summary Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.
View HTML
Toggle Summary Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75
View HTML
Toggle Summary Fluidigm Announces Commencement of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten
View HTML
Toggle Summary Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in the 30 th Annual Piper Jaffray Healthcare Conference in New York :
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of November 6, 2018 , under
View HTML